Management focus is on a strong balance sheet
20/11/23 -"After the fairly decent Q3 results and the guidance cut on costs, a mix of lower operating costs, higher interest income (again) and a lower tax rate have all driven an upgrade to our 2023 EPS ..."
Pages
56
Language
English
Published on
20/11/23
You may also be interested by these reports :
23/07/26
Despite FX headwinds, the Q2 results were ahead of the street’s expectations. The performance was driven by drugs across therapeutic areas, and the ...
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...
21/07/26
The Q2 sales growth was supported by a healthy showing across both segments. The management now expects full-year growth to be at the upper end of ...
21/07/26
The Q2 results exceeded expectations, aided by the strong performance of cancer and neuroscience medicines, healthy growth in immunology offerings, ...